Publications
101
Citations
1,210
Est. group size
—
Recurring co-author estimate
Active years
36
Publishing since 1991
Typically publishes in teams of ~14 · 13% small-team papers (≤3 authors) · across 46 venues
- The TIME trial: Phase II randomized controlled trial of time-of-day–specified nivolumab and ipilimumab for advanced melanoma.
Journal of Clinical Oncology · 2026
- Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract
Cancer Medicine · 2025
- Systemic Toxicity With Hyperglycemia or Diabetic Ketoacidosis After Enfortumab Vedotin: Single-Center Case Series
Annals of Internal Medicine Clinical Cases · 2025
- Clinical Trial Protocol S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2025
- Supplementary Table S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2025
- Supplementary Table S2 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2025
- Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis
Clinical Lung Cancer · 2024
- Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy
Current Oncology · 2024
- Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder
ESMO Open · 2024
- VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic): clinical review in a rapidly emerging field
Leukemia & lymphoma/Leukemia and lymphoma · 2024
- Prognostic factors of relapse in surgically resected small cell neuroendocrine carcinomas of the urothelial tract (SCNEC-URO).
Journal of Clinical Oncology · 2024
- Impact of systemic therapy in clinical T1 small-cell neuroendocrine carcinoma of the bladder
European Urology · 2024
- MORPHOLOGICAL PROGRESSION IN RELAPSING PATIENTS WITH SMALL CELL BLADDER CANCER
Urologic Oncology Seminars and Original Investigations · 2024
- MP53-09 IMPACT OF SYSTEMIC THERAPY IN CLINICAL T1 SMALL-CELL NEUROENDOCRINE CARCINOMA OF THE BLADDER
The Journal of Urology · 2024
- Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis
SSRN Electronic Journal · 2024
- Journal of Clinical Oncology×13
- Blood×4
- The Journal of Urology×3
- Leukemia Research×3
- Leukemia & lymphoma/Leukemia and lymphoma×3
- Taylor M. Weis
Medicine · University of Michigan
- Chia-Jen Liu
Medicine · University of Michigan
- Songzhu Zhao
Medicine · The Ohio State University
- Asrar Alahmadi
Medicine · The Ohio State University
- Lai Wei
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile